KR102451646B1 - Leuconostoc holzapfelli GFC1203H and Fermented Product Manufactured Using Thereof - Google Patents

Abstract

The present invention relates to a novel Leuconostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No. KCTC14077BP), and a fermented product prepared using the same.
Novel New Conostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No. KCTC14077BP) culture provided from the present invention - induction of skin-microbiome change (reduction of acne strain causing inflammation), inflammation Since the effect of reduction and proliferation of dermal papilla cells is excellent, the effect as a cosmetic composition is excellent when it is applied to a cosmetic base as an active ingredient.

Description

Newkonostoc holzapelli GFC1203H strain and fermented product prepared using the same {Leuconostoc holzapfelli GFC1203H and Fermented Product Manufactured Using Thereof}

The present invention relates to a novel New Konostock Holzapelli GFC1203H strain having anti-inflammatory and dermal papilla cell enhancing effects and a fermented product prepared using the same.

The skin ecosystem provides various types of habitat for microorganisms, and a wide range of microorganisms live there. It is known that the human host forms a symbiotic relationship with them and has many positive effects on the host. The skin constitutes various types of habitats, such as indentations and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical barrier and helps to defend against potential hazards and toxic substances from the outside. The skin becomes a connection point with the external environment and is also a gathering place for various microorganisms (fungi, bacteria, viruses and small larvae). In line with the selection of physical and chemical functions, microbes adapt to specialized niches to provide habitat. In general, the skin is cold, acidic, and remains dry. Structurally, the epidermis forms the skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in maintaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum and is separated from the keratinocytes. The epidermis has a shape called a so-called “brick and mortar structure”. The skin tissue undergoes a continuous self-healing process, and the squames that have passed the end of the differentiation process are constantly falling off the skin tissue and repeating the process.

On the other hand, bacteria that ferment sugars to obtain energy and produce a large amount of lactic acid are collectively called lactic acid bacteria. While living in the intestine, lactic acid bacteria play a symbiotic relationship with the digestive system of the human body, and play a role in decomposing fiber and complex protein into important nutrients. In addition, by maintaining an acidic intestinal environment, it suppresses the growth of harmful bacteria, improves diarrhea and constipation, synthesizes vitamins, and inhibits blood cholesterol. Lactobacillus has the property of being able to bind strongly to the intestinal mucosa and epithelial cells, so it helps a lot in intestinal function. In addition, it has an immunomodulatory function, so it is effective in atopy and allergy-related diseases.

In the cosmetic field, lactic acid bacteria cultures have been used since commercialization in 1955, mainly Streptococcus genus, Lactobacillus genus, Lactococcus genus, Leuconostoc genus, Bifidobacterium. ( Bifidobacterium ) Research is actively conducted on the form of raw materials such as filtration or extraction by directly fermenting the culture medium using the genus, etc., and filtering or extraction after inoculation with active materials and fermentation.

Among them, as a technology applied to various uses using the genus Lactobacillus , Korean Patent Publication No. 10-1801764 "Lactobacillus cavetus WIKIN55 having a wool promoting activity and a composition comprising the same, a Korean registered patent Publication No. 10-2137252 "A mixed fermented extract for preventing stress-related hair loss using Lactobacillus plantanum J2K-27 strain, a method for producing the same, and a cosmetic composition containing the mixed fermented extract", etc. are disclosed.

Looking back at the skin ecology, physical and biological factors harmonize to provide a variety of habitats, and furthermore, you will be able to think about the delicate balance between humans and microorganisms. When the balance of the symbiotic relationship is disrupted, skin breakdown and infection occur at the same time.

Accordingly, the present inventors have isolated and identified the New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP), and using this inoculated to MRS medium, and culturing to prepare a fermented product, the scalp - The present invention has been completed by discovering that it can induce changes in the skin-microbiome (reduction of acne strains causing inflammation), reduce inflammation and proliferate dermal papilla cells.

Republic of Korea Patent Publication No. 10-1801764 Republic of Korea Patent Publication No. 10-2137252

An object of the present invention is to provide a novel strain having the effect of inducing changes in the scalp-microbiome (reducing acne strains causing inflammation), reducing inflammation and proliferating dermal papilla cells.

Another object of the present invention is to provide a method for producing a fermented product and a fermented product prepared therefrom, comprising inoculating a novel strain into a medium formulated to maximize efficacious activity, and culturing.

Another object of the present invention is to provide a cosmetic composition comprising a fermented product of a novel strain as an active ingredient.

In order to achieve the above object, the present invention provides a scalp-microbiome (skin-microbiome) change induction (reduction of acne strains causing inflammation), reduction of inflammation and New Connostock holza having the effect of proliferation of dermal papilla cells Pelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) is provided.

In the present invention, the strain is characterized in that it is derived from the scalp of a woman in her twenties.

In addition, the present invention is a method for producing a fermented product comprising the steps of inoculating and culturing the New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) into a medium formulated to maximize efficacy provides

In the present invention, the medium is characterized in that it contains Maltose, Lactose, Glycine, and Inulin.

In addition, in the present invention, the culture is characterized in that it is carried out at 32 ~ 37 ℃ for 90 ~ 130 hours.

In addition, the present invention provides a fermented product fermented with the New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP).

In addition, the present invention provides a cosmetic composition comprising the fermented product as an active ingredient.

In the present invention, the cosmetic composition is for use selected from the group consisting of scalp-microbiome change induction (reduction of acne strains causing inflammation), reduction of inflammation and proliferation of dermal papilla cells. characterized.

New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) provided from the present invention is a scalp-microbiome (skin-microbiome) change induction (reduction of acne strain causing inflammation), reduction of inflammation and Since the proliferation of dermal papilla cells is excellent, the effect as a cosmetic composition is excellent when it is applied to a cosmetic base as an active ingredient.

Figure 1 shows the nucleotide sequence of the New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) according to the present invention.
Figure 2 shows the reduction of C. acnes when the fermented product of the New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) according to the present invention is treated on the skin.
Figure 3 is a graph showing the anti-inflammatory by inflammatory cytokine regulation of the fermented product of New Conostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) according to the present invention.
Figure 4 is a graph showing the dermal papilla cell enhancing effect of the fermented product of New Conostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) according to the present invention.

Therefore, in the present invention, from the scalp of a woman in her twenties, an excellent strain is selected by screening a strain having a scalp-microbiome change induction (reduction of acne strains causing inflammation), reduction of inflammation, and proliferation of dermal papilla cells, and , as a result of 16s rRNA sequencing, it was confirmed that it was a novel microorganism with a nucleotide sequence similar to that of Newconostok Holzapelli. Accordingly, it was named as Leuconostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain and deposited at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center.

Accordingly, the present invention relates to Leuconostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (accession number: KCTC14077BP) (hereinafter abbreviated as 'GFC1203H').

At this time, the GFC1203H strain is characterized in that it is derived from the skin of a woman in her 20s.

In addition, the present invention relates to a method for producing a fermented product comprising the steps of inoculating the GFC1203H strain into a medium formulated to maximize efficacious activity, and culturing.

The medium used for the culture is characterized in that it contains Maltose, Lactose, Glycine, and Inulin. Among them, MRS medium (proteose peptone No.3 10g, beef extract 10g, yeast extract 5g, dextrose 20g, Polyoxyethylene sorbitan monooleate 1g, ammonium citrate 2g, maganessium sulfate 0.1g, manganesse selfate 0.05g, dipotassium phosphate 2g, sodium acetate 5g/ L, pH 6.5) and fermented using a medium to which Maltose 0.5g/L, Lactose 1.0g/L, Glycine 0.5g/L, and Inulin 1.0g/L were added as the basis, the yield of the fermented product was most effectively improved. It is preferable in terms of allowing the reduction of inflammation-inducing strains.

The GFC1203H strain was added to MRS broth containing Maltose, Lactose, Glycine and Inulin from 1.0x10 ⁷ to The step of inoculating and culturing at a level of 1-3% by making the number of bacteria 1.0x10 ⁹ is characterized in that the stationary culture is performed in anaerobic conditions at 32 to 37° C. for 90 to 130 hours. If the culture temperature and time are out of the above range, the culture conditions of the fermenting strain are not suitable, so sufficient scalp-microbiome change induction (reduction of acne strains causing inflammation), reduction of inflammation and dermal papilla cells It is undesirable because not only cannot it exhibit growth, but it also does not result in strain growth.

As described above, the cultured strain is filtered under the conditions of pH 3.8 to 4.2, and then the filtered strain is aged at 20 to 30° C. for 10 to 16 days to prepare a fermented product.

In addition, the fermented product of the present invention New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) is a scalp-microbiome (skin-microbiome) change induction (reduction of acne strain causing inflammation), inflammation It has the effect of reducing and proliferating dermal papilla cells, so it is very effective as a cosmetic composition.

Accordingly, the present invention relates to a cosmetic composition comprising a fermented product fermented with Leuconostoc holzapfelli GFC1203H as an active ingredient.

The cosmetic composition may be for use selected from the group consisting of scalp-microbiome change induction (reduction of acne strains causing inflammation), reduction of inflammation and proliferation of dermal papilla cells.

Induction of skin-microbiome change (reduction of acne strains causing inflammation), reduction of inflammation, and proliferation of dermal papilla cells of the present invention Essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, eye cream, moisture It may have a formulation selected from the group consisting of cream, hand cream, foundation, nutritional essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser, but is not limited thereto. The composition of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.

When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc acid may be used as a carrier component. can

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol aliphatic esters, fatty acid esters of polyethylene glycol or sorbitan, and the like.

When the formulation of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.

In the cosmetic composition for the anti-inflammatory and dermal papilla cell enhancing effect of the present invention, the fermented product may be contained in an amount of 0.01 to 90% by weight, preferably 3 to 15% by weight, based on the total weight of the composition. However, it is not limited thereto, as long as it contains an effective amount capable of inducing changes in the skin-microbiome (reduction of acne strains causing inflammation), reducing inflammation, and proliferating dermal papilla cells.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it is for those of ordinary skill in the art to which the present invention pertains that the scope of the present invention is not limited by these examples according to the gist of the present invention. it will be self-evident

<Example 1> New Konostock Holzapelli GFC1203H ( Leuconostoc holzapfelli Isolation of GFC1203H) strain

Swap the scalp of a woman in her twenties with gauze, shake it in MRS medium, and add 0.1 mL of a sample diluted 10 ^-4 times (volume) to MRS agar medium (Peptospecial 10 g, beef extract 10 g, yeast extract 5 g, Glucose 20 g, Triammonium Citrate 2g, sodium acetate 5g, maganessium sulfate 0.2g, manganesse selfate 0.05g, dipotassium phosphate 2g, Agar 15g, Tween80 1g/L, pH 6.2±0.2, MBcell (Cat.No. MB-M1025)) Incubated for 2 days at 37 ℃ in an incubator. The formed colonies were separated and cultured in pure water, and the formed single colony was isolated after culturing in an anaerobic incubator for 24 hours. Among the isolated strains, the GFC1203H strain, which is excellent in inducing changes in skin-microbiome (reducing acne strains causing inflammation), reducing inflammation, and proliferating dermal papilla cells, was selected.

<Example 2> Selection strain 16s rRNA sequencing analysis

SEQ ID NO: 1: 27F (5' AGA GTT TGA TCM TGG CTC AG 3') and SEQ ID NO: 2: 1492R (5' TAC GGY TAC CTT GTT ACG ACT T 3'), which are the gDNA and universal primers of the finally selected GFC1203H strain Using 16s DNA sequencing analysis, it was confirmed that it was a strain with high homology to Lactobacillus iners , and was named as a New Conostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (SEQ ID NO: 3), and an international microorganism It was deposited with a patent depository institution and was given an accession number KCTC14077BP.

<Example 3> Preparation of fermented product of GFC1203H strain

In order to prepare a fermented product of the isolated GFC1203H strain, Maltose, Lactose, Glycine and Inulin were added to the MRS medium, and then the GFC1203H strain was inoculated with 1% to a number of 1.0x10 ⁹ bacteria. After inoculation, there was no oxygen supply to maintain anaerobic conditions, and stationary culture was performed at 37° C. for 120 hours. After the culture was completed, it was confirmed that the pH was 4.0 (error 0.2), and when it was visually confirmed that the color was dark brown, the culture was finished and a 0.2 μm filter (Millipore) was sterilized. When the filter was completed, a fermentation product of the GFC1203H strain was prepared through a fermentation period of 2 weeks at room temperature.

<Comparative Example 1> Fermented product using general Leuconostoc holzapfelli bacteria

Comparative Example 1 was prepared in the same manner as in <Example 3>, except that the Leuconostoc holzapfelli type strain was used instead of the isolated GFC1203H strain.

<Experimental Example 1> Subject and scalp microbiome sample collection

The samples used in this experiment were tested on subjects who obtained prior consent from the GFC Life Science Research Institute. As the probiotics used in the test, the fermented product of the GFC1203H strain was used. After culturing, the culture solution from which the cells were removed was applied to the subject's facial skin, and skin samples were collected for a total of 72 hours and used for analysis. The method was used and a scalp sample was collected by scrubbing using gauze. The collection of microorganisms on the scalp consisted of pre-treatment, post-treatment, untreated (resting period) and re-treatment groups.

Scalp samples were collected using sterile water and a scraper based on references, and all work was carried out in a clean bench. This study was confirmed to be a reason for exemption from the IRB deliberation criteria.

<Experimental Example 2> Genomic DNA extraction and DNA amplification of microorganisms resident on the scalp

After centrifugation (17,000 rpm/m) of the supernatant of a sample collected from the scalp suspended in 0.85% NaCl, the cells were washed once in sterile physiological saline, and FastDNA SPIN KIT (MP Biomedical, France) was used. and DNA was extracted.

<Experimental Example 3> Confirmation of acne strain inhibition among scalp flora through DGGE analysis

D-code system (Bio-rad, USA) was used for DGGE analysis. The concentration of polyacrylamide gel used was 8%, and 40% polyacrylamide bis-solution 29:1 (3.3% C) (Bio-Rad, USA) was manufactured so that a concentration gradient between 40% and 60% was formed vertically. The denaturants used were 7M urea and 40% (w/v) formamide (Sigma, USA). Fill the D-code system with about 7ℓ of TAE buffer (20 mM Tris, 10 mM acetic acid, 0.5 mM EDTA, pH 8.0), 2Xloading dye (0.05% bromophenol blue, 0.05% xylene cyanol, 70% glycerol) and PCR product were mixed and electrophoresed at 50 V for 800 minutes. After electrophoresis was completed, polyacrylamide gel was stained in Redsafe (Intron, Korea) solution for 15 minutes and a specific band was analyzed. The band intensities of the DGGE results were analyzed by histograms and numerical values using GelCompar2 (Bionumeric, Belgium).

As a result, as can be seen in Figure 2, depending on the treatment of the GFC1203H strain fermented product, it was confirmed that the reduction of the representative harmful strain P. acnes.

<Experimental Example 4> Anti-inflammatory test: Nitric Oxide (NO)

Using the fermented product of Example 3 and Comparative Example 1, the degree of inhibition of nitric oxide was measured in order to confirm the anti-inflammatory activity effect.

RAW 264.7 cells, a type of macrophages, were equally counted and dispensed at a rate of 1.0x10 ⁴ cells/well in a 24 Well plate using DMEM medium containing 1% penicillin/scraptomycin and 10% FBS (fetal bovineserum). Incubated for 24 hours at 37 °C and 5% carbon dioxide conditions. In RAW 264.7 cells cultured for 24 hours, Examples 1 and 2 and Comparative Examples 1 and 2 were mixed with the medium at a concentration of 50 (㎍ / ㎖), 1 ml each was added to each well, and incubator at 37 ° C. and 5% CO ₂ condition was reacted for 24 hours. At this time, LPS (Lipo poly saccharide), an inflammation-inducing factor expressing NO, was treated at a concentration of 1 μg/ml and reacted at 37° C. and 5% carbon dioxide for 24 hours. Next, after taking only the supernatant from each well, 100 ml of the culture solution was placed in a 96 well plate using a Nitric Oxide detection kit in each well, and 50 μl of Griess reagent A (N-1-Naphthylethylenediamine (NEDHC)) and 50 μl of Griess reagent B After adding 50 μl of (Sulfanilamide), each reacted for 10 minutes, absorbance was measured at 540 nm using an ELISA plate reader. The concentration of NO in the cell culture medium was calculated by comparing it with a standard curve for each concentration of sodium nitrite (NaNO2).

division NO production concentration (μM) positive control 15.1±0.94 negative control 67.0±1.05 Example 3 11.2±0.99 Comparative Example 1 58.6±1.22

As a result, as shown in Table 1, Example 3 was confirmed to have a lower nitric oxide production concentration compared to Comparative Example 1, confirming that the nitric oxide production inhibitory effect was excellent. Although the type strain strain of GFC1203H and the control group is Leuconostoc holzapfelli , which has the same scientific name, it can be confirmed that the anti-inflammatory effect of the GFC1203H strain provided in the present invention is much superior. This is judged to be an intrinsic characteristic of the strain itself, which is caused by the difference between strains. Therefore, Leuconostoc holzapfelli GFC1203H was previously used in Leuconostoc holzapfelli . It was confirmed that the strain had an anti-inflammatory effect by inhibiting NO, which could not be confirmed.

This result means that there is an anti-inflammatory effect on the GFC1203H strain (Accession No.: KCTC14077BP) strain ferment.

<Experimental Example 5> Anti-inflammatory test: cytokine inhibition

The inflammatory response is regulated by the production and secretion of inflammatory cytokines along with NO. Therefore, in order to investigate the effect of the strain lysate on the secretion and expression of inflammation-inducing cytokines, the amount of inflammation-inducing cytokines secreted from the culture medium was measured by ELISA after the cells were treated with LPS and various concentrations of lactic acid bacteria from the scalp. assay was used. In addition, changes in the expression of inflammation-inducing cytokines were confirmed through realtime PCR analysis.

As a result, as shown in FIG. 3 , it was confirmed that the secretion and expression of IL-1β, IL-6, and TNF-α induced by LPS treatment decreased in the treatment of the GFC1203H strain (Accession No.: KCTC14077BP) strain. When the scalp-derived microorganism GFC1203H strain (Accession No.: KCTC14077BP) strain was treated, it was confirmed that it was significantly reduced in a concentration-dependent manner even at a low concentration. Through these results, it was confirmed that the fermented product exhibits anti-inflammatory effects through inhibition of the secretion and expression of inflammatory cytokines as well as the regulation of NO, which is an inflammatory product, in the inflammatory response induced by LPS.

<Experimental Example 6> Effect of dermal papilla cell proliferation: cytokine inhibition

Cell proliferation rate was measured by Mosmann's method. The dermal papilla cells were dispensed 2x10 ³ each in a 24 well plate, and 5, 10, and 25 μg/ml of Example 3 and Comparative Example 1 and 10 μM of minoxidil as a positive control group (Sigma, MO, USA) were treated, followed by treatment at 37°C, 5 Incubated for 48 hours and 72 hours under % CO₂. Cell proliferation rate measurement by ERK, Akt inhibitor (PD98059, LY294002; cell signaling, MA, USA) treatment was performed by dispensing 2x10 ³ dermal papilla cells into a 24 well plate, 24 hours later, with inhibitor for 1 hour, and Example 3 to 10 , treated with 25 μg/ml and incubated for 72 hours at 37° C. and 5% CO₂. After incubation, 0.5 mg/mL thiazolyl blue tetrazolium bromide (MTT; Sigma, MO, USA) solution was added and reacted at 37°C for 3 hours, then the supernatant was removed, the formed formazan was dissolved in 1 mL of DMSO, Absorbance was measured.

division Effect of dermal papilla cell proliferation (%) positive control 125.1±1.19 Example 3 131.4±0.58 Comparative Example 1 ND

As a result of the test, the fermented product of the GFC1203H strain showed a superior dermal papilla cell proliferation effect than the positive control, but the type stain strain of Comparative Example 1 did not show any dermal papilla cell proliferation effect. Although the type strain strain of GFC1203H and the control group is Leuconostoc holzapfelli , which has the same scientific name, it is judged to be an intrinsic characteristic of the strain itself displayed by the difference in strain. Therefore, it was confirmed that Leuconostoc holzapfelli GFC1203H provided by the present invention is a strain having the effect of preventing hair growth and hair loss by dermal papilla cell proliferation, which was not previously seen in Leuconostoc holzapfelli .

These results mean that the GFC1203H strain (Accession No.: KCTC14077BP) strain has an effect of preventing hair growth and hair loss by proliferation of dermal papilla cells.

As a specific part of the present invention has been described in detail above, for those of ordinary skill in the art, it is clear that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereby. will be. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.

Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (KCTC) KCTC14077BP 20191217

<110> GFC Life Science Co., Ltd. <120> Leuconostoc holzapfelli GFC1203H and Fermented Product Manufactured Using Thereof <130> p20201209 <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Universal primer 27F <400> 1 agagtttgat cmtggctcag 20 <210> 2 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Universal primer 1492R <400> 2 tacggytacc ttgttacgac tt 22 <210> 3 <211> 1276 <212> DNA <213> Artificial Sequence <220> <223> Leuconostoc holzapfelli GFC1203H <400> 3 cgtggataac ctgcctcaag gctggggata acattggaa acagatgcta ataccgaata 60 aaacttagta tcgcatgata tcaagttaaa aggcgctacg gcgtcaccta gagatggatc 120 cgcggtgcat tagttagttg gtggggtaaa ggcttaccaa gacgatgatg catagccgag 180 ttgagagact gatcggccac attgggactg agacacggcc caaactccta cgggaggctg 240 cagtagggaa tcttccacaa tgggcgcaag cctgatggag caacgccgcg tgtgtgatga 300 aggctttcgg gtcgtaaagc actgttgtat gggaagaaat gctaaaatag ggaatgattt 360 tagtttgacg gtaccatacc agaaagggac ggctaaatac gtgccagcag ccgcggtaat 420 acgtatgtcc cgagcgttat ccggatttat tgggcgtaaa gcgagcgcag acggttgatt 480 aagtctgatg tgaaagcccg gagctcaact ccggaatggc attggaaact ggttaacttg 540 agtgttgtag aggtaagtgg aactccatgt gtagcggtgg aatgcgtaga tatatggaag 600 aacaccagtg gcgaaggcgg cttactggac aacaactgac gttgaggctc gaaagtgtgg 660 gtagcaaaca ggattagata ccctggtagt ccacaccgta aacgatgaat actaggtgtt 720 aggaggtttc cgcctcttag tgccgaagct aacgcattaa gtattccgcc tggggagtac 780 gaccgcaagg ttgaaactca aaggaattga cggggacccg cacaagcggt ggagcatgtg 840 gtttaattcg aagcaacgcg aagaacctta ccaggtcttg acatcctttg aagcttttag 900 agatagaagt gttctcttcg gagacaaagt gacaggtggt gcatggtcgt cgtcagctcg 960 tgtcgtgaga tgttgggtta agtcccgcaa cgagcgcaac ccttattgtt agttgccagc 1020 attcagttgg gcactctagc gagactgccg gtgacaaacc ggaggaaggc ggggacgacg 1080 tcagatcatc atgcccctta tgacctgggc tacacacgtg ctacaatggc gtatacaacg 1140 agttgccaac ctgcgaaggt gagctaatct cttaaagtac gtctcagttc ggactgcagt 1200 ctgcaactcg actgcacgaa gtcggaatcg ctagtaatcg cggatcagca cgccgcggtg 1260 aatacgttcc cgggtc 1276

Claims (7)

Novel Neuconostoc holzapfelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) having the effect of reducing Propionibacterium acnes , reducing inflammation, and proliferating dermal papilla cells.
According to claim 1, wherein the strain is a novel New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP), characterized in that it is derived from the scalp of a woman in her twenties.
A novel New Conostoc holzapelli GFC1203H ( Leuconostoc holzapfelli GFC1203H) strain (Accession No.: KCTC14077BP) is inoculated into a medium containing maltose, lactose, glycine and inulin, and cultured A method for producing a fermented product, comprising the steps of.
The method of claim 3, wherein the culturing is performed at 32 to 37° C. for 90 to 130 hours.
A fermented product fermented with a novel Leuconostoc holzapfelli GFC1203H strain (Accession No.: KCTC14077BP).
A cosmetic composition comprising the fermented product of claim 5 as an active ingredient.
The cosmetic composition according to claim 6, wherein the cosmetic composition is for use selected from the group consisting of Propionibacterium acnes reduction, inflammation reduction, and proliferation effect of dermal papilla cells.

Images